The pharmaceutical giant reported net income of $1.82 billion, or $1.02 per share, a sharp recovery from the $22 million loss recorded during the same period last year. On an adjusted basis, AbbVie earned $2.71 per share, surpassing the $2.65 average estimate from analysts polled by FactSet. Total net revenue climbed 10%, driven largely by an 18% surge in both the immunology and neuroscience divisions.

Strengthening the Immunology Pipeline

The company’s strategic pivot away from Humira—which saw a 26% decline in sales due to low-cost competitors—appears to be gaining momentum. Growth was primarily fueled by the blockbuster success of Skyrizi and Rinvoq, which saw revenue jumps of 32.5% and 29.5%, respectively. These two therapies now anchor a portfolio that generated $8.63 billion in quarterly revenue, while the neuroscience segment contributed another $2.96 billion to the top line.

Looking ahead, AbbVie issued optimistic long-term guidance that exceeded market projections. The company expects adjusted earnings for 2026 to fall between $14.37 and $14.57 per share. This forecast sits comfortably above the $14.27 per share currently anticipated by Wall Street analysts, signaling confidence in the sustained trajectory of its newer clinical offerings.